絞り込み

16645

広告

「"Solomon SR "[Author]」の検索結果

53件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program.

Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy.

Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Safety and efficacy of rituximab-based first line treatment of chronic GVHD.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older.

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, KIR Genotyping, and Other Clinical Variables.

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): a Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint.

Current GVHD-Free, Relapse-Free Survival - a Dynamic Endpoint to Better Define Efficacy Following Allogenic Transplant.

Impact of Donor Type on Outcome Following Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

T cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCY) is an Effective Salvage for Patients Relapsing after an HLA- Matched Related (MRDT) or a Matched Unrelated Donor Transplantation (MUDT).

Factors Predicting GVHD Free, Relapse Free Survival (GRFS) After Allogeneic Hematopoietic Cell Transplantation: A Multivariable Analysis of 531 Allografts from a Single Center.

  1. 1
  2. 2
  3. 3
Sort by
※並べ替えは表示に時間がかかります